Substance / Medication

Ipratropium

Overview

Active Ingredient
ipratropium
RxNorm CUI
7213

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

20 trials linked to this intervention

20
Total Trials
0
Recruiting
9
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Ipratropium Bromide Nasal Spray in Non-Allergic Rhinitis: A Systematic Review and Meta-Analysis.
El Khoury Patrick, Abou Hamad Walid, Khalaf Michel G et al. · Laryngoscope · 2023
PMID: 37067019Meta-Analysis
The use of ipratropium bromide for treating moderate to severe asthma exacerbations in pediatric patients in an emergency setting: A cost-effectiveness analysis.
Rodriguez-Martinez Carlos E, Sossa-Briceño Monica P, Buendia Jefferson Antonio · Pediatr Pulmonol · 2021
PMID: 34473916Meta-Analysis
Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.
Xu Hongzhen, Tong Lin, Gao Peng et al. · PLoS One · 2021
PMID: 33621253Meta-AnalysisFull text (PMC)
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne Leanne, Irvin-Sellers Melanie J, White John · Cochrane Database Syst Rev · 2015
PMID: 26391969Meta-AnalysisFull text (PMC)
Intranasal ipratropium bromide for the common cold.
AlBalawi Zaina H, Othman Sahar S, Alfaleh Khalid · Cochrane Database Syst Rev · 2013
PMID: 23784858Meta-AnalysisFull text (PMC)
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne Leanne, Irvin-Sellers Melanie J, White John · Cochrane Database Syst Rev · 2013
PMID: 24043433Meta-Analysis
Intranasal ipratropium bromide for the common cold.
Albalawi Zaina H, Othman Sahar S, Alfaleh Khalid · Cochrane Database Syst Rev · 2011
PMID: 21735425Meta-Analysis
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Appleton S, Jones T, Poole P et al. · Cochrane Database Syst Rev · 2006
PMID: 16625543Meta-AnalysisFull text (PMC)
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
Appleton S, Jones T, Poole P et al. · Cochrane Database Syst Rev · 2006
PMID: 16856113Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ipratropium (substance)
SNOMED CT
372518007
UMLS CUI
C0027235
RxNorm CUI
7213

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
20
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.